AGIO AGIOS PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1439222 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY214.4%
TTM net income YoY7.1%
TTM EPS YoY10.0%
Revenue 3-yr CAGR80.3%
Net income 3-yr CAGR—
Margins
Gross margin93.8%
Operating margin-297.7%
Net margin-264.8%
FCF margin-238.5%
EBITDA margin—
Returns
ROE-32.9%
ROA-30.4%
ROIC (approx.)-32.4%
Asset turnover0.11x
Leverage & solvency
Liabilities / assets8.0%
Debt / equity0.00x
Current ratio9.69x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue3.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $55.38M | $44.74M | $20.75M | $19.97M | $12.88M | $12.46M | $8.73M | $10.73M |
| Cost of revenue | $2.52M | $3.00M | $1.32M | $1.88M | $1.68M | $1.70M | $1.08M | $1.26M |
| Gross profit | $52.86M | $41.75M | $19.43M | $18.09M | $11.20M | $10.75M | $7.64M | $9.47M |
| R&D expense | $73.49M | $100.75M | $81.15M | $88.06M | $86.80M | $91.94M | $72.74M | $82.81M |
| SG&A expense | $56.53M | $51.55M | $48.30M | $51.61M | $41.27M | $45.87M | $41.53M | $51.70M |
| Operating income | -$77.16M | -$110.55M | -$110.03M | -$121.58M | -$116.87M | -$127.06M | -$106.63M | -$125.04M |
| Pretax income | — | — | — | -$109.06M | -$103.43M | — | — | -$105.40M |
| Income tax | — | — | — | -$1.02M | $0 | — | — | -$8.88M |
| Net income | -$65.05M | -$100.70M | -$99.11M | -$108.04M | -$103.43M | -$112.02M | -$89.29M | -$96.52M |
| EPS (basic) | -1.09 | -1.69 | -1.69 | — | -1.78 | -1.93 | -1.55 | — |
| EPS (diluted) | -1.09 | -1.69 | -1.69 | — | -1.78 | -1.93 | -1.55 | — |
| Weighted avg. shares (diluted) | 59.71M | 59.49M | 58.78M | — | 58.14M | 57.93M | 57.46M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $128.55M | $99.65M | $113.60M | $89.13M | $92.71M | $80.87M | $78.96M | $76.25M |
| Short-term investments | $501.46M | $517.93M | $623.44M | $765.29M | $860.15M | $858.07M | $814.41M | $817.46M |
| Inventory | $37.84M | $35.75M | $35.09M | $32.92M | $32.03M | $30.85M | $29.61M | $27.62M |
| Current assets | $752.10M | $717.67M | $834.84M | $942.05M | $1.03B | $1.02B | $968.62M | $965.60M |
| PP&E, net | $10.36M | $9.95M | $10.57M | $10.78M | $10.68M | $10.58M | $11.07M | $11.68M |
| Total assets | $1.06B | $1.11B | $1.18B | $1.30B | $1.39B | $1.47B | $1.56B | $1.66B |
| Current liabilities | $77.59M | $70.22M | $58.84M | $82.21M | $74.76M | $70.41M | $52.37M | $81.16M |
| Total liabilities | $84.70M | $82.40M | $75.88M | $104.11M | $101.38M | $101.68M | $88.99M | $122.24M |
| Shareholders' equity | $979.34M | $1.03B | $1.11B | $1.19B | $1.28B | $1.37B | $1.47B | $1.54B |
| Shares outstanding | 59.78M | 59.60M | 59.34M | 58.45M | 58.28M | 58.04M | 57.89M | 57.16M |
| Cash flow statement | ||||||||
| Operating cash flow | -$59.24M | -$57.31M | -$118.92M | -$96.21M | -$88.15M | -$77.12M | -$111.49M | -$133.17M |
| Capital expenditure | $1.18M | $1.21M | $769,000 | $1.12M | $1.55M | $875,000 | $766,000 | $967,000 |
| Free cash flow | -$60.42M | -$58.52M | -$119.69M | -$97.33M | -$89.71M | -$78.00M | -$112.25M | -$134.13M |
| Investing cash flow | $83.96M | $40.21M | $141.31M | $90.08M | $95.56M | $78.97M | $112.59M | -$49.16M |
| Financing cash flow | $4.18M | $3.15M | $2.08M | $2.56M | $4.43M | $65,000 | $1.62M | $4.84M |
| Stock-based compensation | $16.67M | $15.94M | $15.54M | $14.12M | $12.38M | $14.69M | $11.36M | $10.90M |
Free plan shows the latest 8 periods; Pro shows all 59 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.